New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
16:17 EDTAEZSAeterna Zentaris announces at the market issuance program
Aeterna Zentaris announced that it has entered into an at the market issuance sales agreement with MLV & Co. under which the company may, at its discretion, from time to time during the term of the sales agreement, sell up to a maximum of 14.02M of its common shares through ATM issuances up to an aggregate amount of $15M. MLV will act as sales agent for any sales made under the ATM. The common shares will be sold at market prices prevailing at the time of the sale of common shares, and, as a result, prices may vary.
News For AEZS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
07:32 EDTAEZSAeterna Zentaris says Macrilen study in AGHD meets EMA study-design expectations
Aeterna Zentaris announced that it has received written scientific advice from the European Medicines Agency regarding the further development plan, including the study design, for the new confirmatory Phase 3 clinical study of Macrilen for use in evaluating adult growth hormone deficiency, following a Scientific Advice Meeting that was held earlier this month. As a result of the advice, the company believes that the confirmatory Phase 3 study that was discussed with the U.S. Food & Drug Administration last March, meets the EMA's study-design expectations. "We are committed to moving forward swiftly with the development of Macrilen in AGHD. We believe that completion of the confirmatory Phase 3 study and the QT study will take 15 to18 months and will require a combined expenditure of between $5M-$6M. We have the resources necessary to bring this product to market and intend to do so as rapidly as possible, pending regulatory approvals," said David Dodd, Chairman and CEO.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use